• Publications
  • Influence
Enzalutamide in metastatic prostate cancer before chemotherapy.
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
To evaluate, in the ongoing EPC trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer. Expand
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease. Expand
Brain Energy Metabolism and Blood Flow Differences in Healthy Aging
A possible mechanism of progression from healthy to unhealthy brain aging is established, as the regions most affected by age are the areas that are most vulnerable to neurodegeneration. Expand
Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.
Patients with prostate cancer and bone metastases should be treated within prospective trials evaluating the role of cytoreductive prostatectomy in low-volume, bone metastatic prostate cancer, because of the unclear oncological effect of CRP. Expand
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median
It is confirmed that bicalutamide provides benefit in patients with locally advanced disease and early or adjuvant hormonal therapy for patients at low risk of disease progression, such as those with localized disease, is not appropriate. Expand
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. Expand
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
According to data from longer follow-up, enzalutamide continued to provide benefit over placebo in patients with metastatic castration-resistant prostate cancer, and this final analysis of PREVAIL provides more complete assessment of the clinical benefit of enzAlutamide. Expand
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function
In the absence of sexual interest, the treatment of sexual dysfunction becomes less relevant and therefore hormonal treatments for advanced prostate cancer which spare sexual interest are needed. Expand